First Heart Patient Treated in Adipose Stem Cell Trial

Cytori's Cardiovascular Stem Cell Study Initiated

08-Feb-2007

Cytori Therapeutics and Hospital Gregorio Maranon in Madrid, Spain treated the first patient in Cytori's randomized clinical trial investigating the safety and feasibility of adipose-derived stem and regenerative cells as a therapy for cardiovascular disease.

The study, designated as the 'PRECISE' trial, will enroll patients suffering from chronic myocardial ischemia, a severe form of end-stage coronary artery disease. Patients in the study will receive their own adult stem and regenerative cells, thereby avoiding the risk of rejection or disease transmission that exists with donor stem cells and the controversy associated with embryonic stem cells. Once introduced into a patient's heart, the cells have shown preclinically to help the body improve blood supply that can restore circulation to the heart.

Adipose tissue, commonly known as fat, is the human body's richest known source of stem cells, as well as other cells that are believed to contribute to repair and healing, referred to as "regenerative cells." Due to its abundance and accessibility in the body, adipose tissue represents an ideal source for immediate access to a patient's own stem and regenerative cells. For the PRECISE study, stem and regenerative cells are obtained at the bedside from the patients' own adipose tissue and made available in real-time using Cytori's Celution(TM) System.

Other news from the department research and development

More news from our other portals

All FT-IR spectrometer manufacturers at a glance